Related Experiment Video

Updated: Jan 23, 2026

De Novo Generation of Somatic Stem Cells by YAP/TAZ
13:05

De Novo Generation of Somatic Stem Cells by YAP/TAZ

Published on: May 7, 2018

9.6K

YAP/TAZ Signaling and Resistance to Cancer Therapy

Chan D K Nguyen1, Chunling Yi1

  • 1Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.

Trends in Cancer
|June 9, 2019
PubMed

Insights

Drug resistance in cancer may be driven by YAP/TAZ signaling. Targeting YAP/TAZ or its downstream effects with existing or novel therapies, like BET inhibitors, shows promise for overcoming treatment resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Drug resistance is a significant obstacle in cancer therapy.
  • YAP/TAZ signaling pathway deregulation is increasingly recognized as a key mechanism for both intrinsic and acquired resistance to various cancer treatments.
  • YAP/TAZ also plays a crucial role in tumor immune evasion by promoting PD-L1 and cytokine expression.

Purpose of the Study:

  • To review the role of YAP/TAZ signaling in cancer drug resistance.
  • To explore therapeutic strategies targeting YAP/TAZ to overcome resistance.
  • To highlight the potential of FDA-approved drugs and BET inhibitors in this context.

Main Methods:

  • Literature review and synthesis of emerging evidence on YAP/TAZ signaling in cancer drug resistance.
  • Analysis of therapeutic approaches targeting YAP/TAZ pathways.
  • Evaluation of clinical and preclinical data on drugs affecting YAP/TAZ.

Main Results:

  • YAP/TAZ pathway dysregulation contributes significantly to resistance against chemotherapy and targeted therapies.
  • YAP/TAZ-driven PD-L1 and cytokine expression facilitates tumor immune evasion.
  • Indirect YAP/TAZ inhibition via FDA-approved drugs and BET inhibitors demonstrates potential in preclinical and clinical settings.

Conclusions:

  • YAP/TAZ signaling is a critical mediator of cancer drug resistance and immune evasion.
  • Targeting YAP/TAZ, directly or indirectly, offers a promising strategy to improve therapeutic efficacy.
  • Further investigation into YAP/TAZ inhibitors and combination therapies is warranted to overcome treatment resistance.
Keywords:
Cancer therapy resistanceHippo pathwayTAZYAP

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K
Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring08:45

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring

Published on: November 13, 2012

14.3K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.7K
Resistivity01:22

Resistivity

When a voltage is applied to a conductor, an electrical field is generated, and charges in the conductor feel the force due to the electrical field. The current density that results depends on the electrical field and the properties of the material. In some materials, including metals at a given temperature, the current density is approximately proportional to the electrical field. In these cases, the current density can be modeled as:
4.4K
Resistance01:19

Resistance

When a current moves through any conductor, the conductor causes some level of difficulty for the current to flow. The measure of that difficulty is known as the resistance of the material and is represented by R. Every material has its own resistance. In the case of conductors, heat is emitted whenever a current passes through them. Resistance depends on the resistivity of the material. Resistivity is a characteristic of the material used to fabricate electrical components, whereas the...
5.7K